EA202000248A1 - ANTI-SARS-CoV-2 VIRAL ANTIPROVIR - Google Patents

ANTI-SARS-CoV-2 VIRAL ANTIPROVIR

Info

Publication number
EA202000248A1
EA202000248A1 EA202000248A EA202000248A EA202000248A1 EA 202000248 A1 EA202000248 A1 EA 202000248A1 EA 202000248 A EA202000248 A EA 202000248A EA 202000248 A EA202000248 A EA 202000248A EA 202000248 A1 EA202000248 A1 EA 202000248A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antiprovir
cov
sars
viral
coronovirus
Prior art date
Application number
EA202000248A
Other languages
Russian (ru)
Inventor
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Original Assignee
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович ИВАЩЕНКО, Александр Васильевич ИВАЩЕНКО, Николай Филиппович САВЧУК, Алёна Александровна Иващенко, Владимир Григорьевич ЛОГИНОВ, Михаил ТОПР filed Critical Андрей Александрович ИВАЩЕНКО
Priority claimed from PCT/RU2020/000328 external-priority patent/WO2021221532A1/en
Publication of EA202000248A1 publication Critical patent/EA202000248A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к новому противо-SARS-CoV-2 вирусному средству Антипровир, предназначенному для профилактики и лечения короновирусного заболевания COVID-19. Применение фармацевтической композиции, в том числе Апротекс, Гордокс и Аэрус, включающие в качестве активного компонента апротинин и вспомогательные вещества, в качестве противо-SARS-CoV-2 вирусного лекарственного средства Антипровир для профилактики и лечения короновирусного заболевания COVID-19. Лекарственное средство Антипровир для профилактики и лечения короновирусного заболевания COVID-19 представляет собой фармацевтическую композицию, содержащую 0,1-0,2 вес.% апротинина, необязательно 0,2-1,0 вес.% вспомогательных веществ и остальное - вода для инъекций.The invention relates to a new anti-SARS-CoV-2 viral agent Antiprovir, intended for the prevention and treatment of coronovirus disease COVID-19. The use of a pharmaceutical composition, including Aprotex, Gordox and Aerus, including aprotinin and excipients as an active ingredient, as an anti-SARS-CoV-2 viral drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19. The drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19 is a pharmaceutical composition containing 0.1-0.2 wt.% aprotinin, optionally 0.2-1.0 wt.% excipients and the rest is water for injection.

EA202000248A 2020-07-03 2020-07-03 ANTI-SARS-CoV-2 VIRAL ANTIPROVIR EA202000248A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/RU2020/000328 WO2021221532A1 (en) 2020-04-30 2020-07-03 Sars-cov-2 antiviral drug antiprovir
RU2020000328 2020-07-03

Publications (1)

Publication Number Publication Date
EA202000248A1 true EA202000248A1 (en) 2022-01-31

Family

ID=80631221

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202000248A EA202000248A1 (en) 2020-07-03 2020-07-03 ANTI-SARS-CoV-2 VIRAL ANTIPROVIR

Country Status (1)

Country Link
EA (1) EA202000248A1 (en)

Similar Documents

Publication Publication Date Title
MX2023000798A (en) Functionalized peptides as antiviral agents.
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
MX2023005984A (en) Novel spiropyrrolidine derived antiviral agents.
RU2329050C2 (en) Combination of cytochrome-p450-dependent protease inhibitors
EA200602130A1 (en) SUBSTITUTED ARYLACYLTIOMETRIC AND RELATED COMPOUNDS; VIRUS REPLICATION INHIBITORS
AR032556A1 (en) IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION
MX2023005983A (en) Novel spiropyrrolidine derived antiviral agents.
EA201490163A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
EA202190960A1 (en) CONDENSED PYRROLINES THAT ACT AS INHIBITORS OF UBIKVITIN SPECIFIC PROTEASE 30 (USP30)
MX2023001756A (en) Functionalized peptides as antiviral agents.
EA202000347A1 (en) ANTI-SARS-CoV-2 VIRAL AGENT ANTIPROVIR
SE9901573D0 (en) New compounds
RU2012157328A (en) MEDICINAL PRODUCT FOR PREVENTIVE AND / OR THERAPEUTIC TREATMENT OF DEMENTIA BY ALZHEIMER TYPE
EA202190544A1 (en) APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES
MX2021014161A (en) Methods of treating sjã–gren's syndrome using a bruton's tyrosine kinase inhibitor.
EA202000248A1 (en) ANTI-SARS-CoV-2 VIRAL ANTIPROVIR
EA202000165A1 (en) ANTI-PHK VIRAL, INCLUDING ANTI-SARS-CoV-2 VIRAL PHARMACEUTICAL COMPOSITION AVIFAVIR
AR046146A1 (en) TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR SPRAYING THAT INCLUDE AN ACTIVE AGENT, A VP / VA COPOLYMER AND A NON-WATER VEHICLE
SE9901572D0 (en) New compounds
EA200400348A1 (en) CYPLATINE COMPOSITIONS OF REDUCED TOXICITY AND METHODS OF THEIR APPLICATION
CR20230192A (en) Solid formulation
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
RU2020124373A (en) PREVENTIVE AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF CATARACT, APPLICATION OF A PPAR ACTIVATOR FOR THE SAME PURPOSE AND EYE DROPS
KR950702413A (en) Method of using 2- (4- (4-chlorophenyl) cyclohexyl) -3-hydroxy-1,4-naphthoquinone for cancer treatment (USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL)- 3-HYDROXY-1,4-NAPHTHOQUINONE FOR THE TREATMENT OF CANCER)
EA201900293A3 (en) TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES